SCHEMBL1390684

SCHEMBL1390684

COCOc1cc(C#Cc2ccc3c(c2)OCO3)ccc1C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
TSHR P16473 3/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
MAPT P10636 2/20 0.51
RAB9A P51151 5/20 0.46
NPC1 O15118 5/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GCK P35557 1/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 1/20 0.41
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10280413 0.85 ALDH1A1 (0.53) ALDH1A1TSHRCYP3A4CYP2D6CYP2C9
SCHEMBL1390532 0.84 ACACB (0.48) ALDH1A1TSHRCYP3A4CYP2D6CYP2C9
SCHEMBL1390724 0.82 RARG (0.44) ALDH1A1TSHRCYP3A4CYP2D6CYP2C9
SCHEMBL7920809 0.81 CA12 (0.48) ALDH1A1TSHRMAPTRAB9ANPC1
SCHEMBL1390484 0.80 TDP1 (0.49)
SCHEMBL1390907 0.78 ACACB (0.48)
SCHEMBL1391012 0.78 ACACB (0.46) ALDH1A1MAPTKDM4EL3MBTL1HPGD
SCHEMBL1391035 0.77 ACACB (0.46) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL1391085 0.75 PTPN1 (0.51) ALDH1A1RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL1390842 0.74 ACACB (0.48) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB ALDH1A1 762/4885TSHR 3927/4885CYP3A4 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.